18F-FP-CIT PET/CT in a case of probable sporadic Creutzfeldt-Jakob disease with parkinsonism as initial symptom

Tang, Songhan; Dou, Xiaofeng; Zhang, Ying

doi:10.1080/19336896.2022.2093078

Cited by 6 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The similarity between VV2-CJD and PD was also evident at the transcriptomic level, where differential gene expression and functional analysis confirmed and expanded the finding of impairment of some key biological processes associated with PD, such as dopamine secretion, regulation of calcium release, GABA signaling, and mitochondrial permeability in sCJD VV2. This finding is supported by the high prevalence of parkinsonism and other movement disorders in prion diseases [33][34][35][36][37]. Specifically, VV2 and MV2 subtypes exhibit the most severe neuropathological changes, as defined by regional lesion profiles, in the midbrain (substantia nigra) and striatum within the spectrum of sCJD subtypes [2].…”

Section: Discussionmentioning

confidence: 79%

Genomic, transcriptomic and RNA editing analysis of human MM1 and VV2 sporadic Creutzfeldt-Jakob disease

Tarozzi

Baiardi

Sala

et al. 2022

acta neuropathol commun

View full text Add to dashboard Cite

Creutzfeldt-Jakob disease (CJD) is characterized by a broad phenotypic spectrum regarding symptoms, progression, and molecular features. Current sporadic CJD (sCJD) classification recognizes six main clinical-pathological phenotypes. This work investigates the molecular basis of the phenotypic heterogeneity of prion diseases through a multi-omics analysis of the two most common sCJD subtypes: MM1 and VV2. We performed DNA target sequencing on 118 genes on a cohort of 48 CJD patients and full exome RNA sequencing on post-mortem frontal cortex tissue on a subset of this cohort. DNA target sequencing identified multiple potential genetic contributors to the disease onset and phenotype, both in terms of coding, damaging-predicted variants, and enriched groups of SNPs in the whole cohort and the two subtypes. The results highlight a different functional impairment, with VV2 associated with higher impairment of the pathways related to dopamine secretion, regulation of calcium release and GABA signaling, showing some similarities with Parkinson’s disease both on a genomic and a transcriptomic level. MM1 showed a gene expression profile with several traits shared with different neurodegenerative, without an apparent distinctive characteristic or similarities with a specific disease. In addition, integrating genomic and transcriptomic data led to the discovery of several sites of ADAR-mediated RNA editing events, confirming and expanding previous findings in animal models. On the transcriptomic level, this work represents the first application of RNA sequencing on CJD human brain samples. Here, a good clusterization of the transcriptomic profiles of the two subtypes was achieved, together with the finding of several differently impaired pathways between the two subtypes. The results add to the understanding of the molecular features associated with sporadic CJD and its most common subtypes, revealing strain-specific genetic signatures and functional similarities between VV2 and Parkinson’s disease and providing preliminary evidence of RNA editing modifications in human sCJD.

show abstract

Section: Discussionmentioning

confidence: 79%

Genomic, transcriptomic and RNA editing analysis of human MM1 and VV2 sporadic Creutzfeldt-Jakob disease

Tarozzi

Baiardi

Sala

et al. 2022

acta neuropathol commun

View full text Add to dashboard Cite

show abstract

Imaging Procedure and Clinical Studies of [18F]FP-CIT PET

Sung,

Oh,

Kim

2024

Nucl Med Mol Imaging

View full text Add to dashboard Cite

N-3-[ 18 F]fluoropropyl-2β-carbomethoxy-3β-4-iodophenyl nortropane ([ 18 F]FP-CIT) is a radiopharmaceutical for dopamine transporter (DAT) imaging using positron emission tomography (PET) to detect dopaminergic neuronal degeneration in patients with parkinsonian syndrome. [ 18 F]FP-CIT was granted approval by the Ministry of Food and Drug Safety in 2008 as the inaugural radiopharmaceutical for PET imaging, and it has found extensive utilization across numerous institutions in Korea. This review article presents an imaging procedure for [ 18 F]FP-CIT PET to aid nuclear medicine physicians in clinical practice and systematically reviews the clinical studies associated with [ 18 F]FP-CIT PET.

show abstract

Involvement of the nigrostriatal system in Gerstman–Sträussler–Scheinker disease with the PRNP-P102L mutation

Ono,

Suzuyama,

Minagawa

et al. 2024

Journal of the Neurological Sciences

View full text Add to dashboard Cite

18F-FP-CIT PET/CT in a case of probable sporadic Creutzfeldt-Jakob disease with parkinsonism as initial symptom

Cited by 6 publications

References 13 publications

Genomic, transcriptomic and RNA editing analysis of human MM1 and VV2 sporadic Creutzfeldt-Jakob disease

Genomic, transcriptomic and RNA editing analysis of human MM1 and VV2 sporadic Creutzfeldt-Jakob disease

Imaging Procedure and Clinical Studies of [18F]FP-CIT PET

Involvement of the nigrostriatal system in Gerstman–Sträussler–Scheinker disease with the PRNP-P102L mutation

Contact Info

Product

Resources

About